Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P14784 (
IL-2 receptor
)
3,849
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The authors used Wenger's vegetative nervous balance factor analysis to measure vegetative nervous function of 75 patients with vertigo revealing enhancement of sympathetic nervous function. The proliferation activity of
IL-2 receptor
was determined by the amount of 3H-TdR incorporated cpm in the peripheral blood lymphocyte after exogenous IL-2 stimulation (Lymphocult-T). The authors used this technique to measure the activity of
IL-2 receptor
in 49 patients with hepatitis and vertigo. The results showed that the activity of
IL-2 receptor
in patients with or without vertigo was lower than the controls (P less than 0.001). And patients with vertigo showed lower activity of
IL-2 receptor
than that without (P less than 0.01). In these patients with
asthenia
-syndrome the activity of
IL-2 receptor
was lower than those with
asthenia
syndrome. The activity of
IL-2 receptor
in these patients with long course was lower than those with short course. The difference of sex and age was not significant. The above results suggest that "Wind" in TCM might be related to the enhancement of sympathetic nervous function and the activity of
IL-2 receptor
.
...
PMID:[Vegetative nervous function and interleukin-2 receptor in patients with vertigo]. 237 96
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics, and possible antitumor activity of a ligand fusion-protein, DAB389IL-2, in a phase I trial. This was a multicenter, open-label, dose-escalation trial. Patients with preserved organ function and histologically confirmed relapsed cutaneous T-cell lymphoma (CTCL), other non-Hodgkin's lymphomas (NHL), or Hodgkin's disease (HD) were eligible if their cancer was shown to express the interleukin (IL)-2 receptor by an immunohistochemical assay for the p55 or the p75 subunit. Patients received up to eight courses of DAB389IL-2 given as a short intravenous infusion daily for 5 days with subsequent courses every 21 days. The maximum tolerated dose (MTD) and tumor response was determined according to standard criteria. Seventy-three patients (44 men/29 women), aged 16 to 81 years (mean, 50.7) with CTCL (n = 35), NHL (n = 17), and HD (n = 21) were enrolled. The patients were extensively treated, failing 0 to 15 previous therapies (median, 4). Patients received one to six courses (mean, 3.3) of DAB389IL-2 over a range of 3 to 31 micrograms/kg/day. The dose-limiting toxicity was
asthenia
, establishing the maximum tolerated dose of 27 micrograms/kg/day. Approximately half of all patients had significant titers of antibody to diphtheria toxin or to DAB389IL-2 at the time of enrollment compared with 92% with titers at the end of treatment. The presence of antibody did not preclude clinical response. There were five complete (CR) and eight partial (PR) remissions in patients with CTCL with one CR and two PR occurring in NHL. The median time to response was 2 months and the duration of response was 2 to 39+ months. No responses were documented in patients with HD. DAB389IL-2 is well tolerated with an MTD of 27 micrograms/kg/day. This ligand fusion-protein showed antitumor effects in patients with
IL-2 receptor
expressing CTCL and NHL. Additional trials in these diseases are warranted.
...
PMID:Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. 942 92
